CAJICA, Colombia – Privately held Inosan Biopharma SA De Cv, of Mexico City, is racing to develop a biological treatment to cure COVID-19 patients. Inosan has mastered the technique of using horses to produce antibodies to heal patients bitten by poisonous creatures, such as snakes, spiders and scorpions.
PERTH, Australia – Starpharma Holdings Ltd. completed a AU$45 million (US$32 million) placement to domestic and international investors that will see it advance its COVID-19 antiviral nasal spray. The treatment is based on the company’s antiviral dendrimer, SPL-7013, which inactivates viruses by blocking the interaction between viral surface proteins and the human cell receptor proteins.
LONDON – Oxford Immunotec plc is aiming to plug a significant gap in the COVID-19 diagnostics landscape, with the development of a commercial clinical grade test for quantifying T cell responses to the SARS-CoV-2 virus. T-Spot Discovery SARS-CoV-2, currently available for research use only, is based on the same automated technology as the company’s tuberculosis diagnostic, which is approved for use in more than 60 countries.
TORONTO – Toronto-based Oncall Health Inc. has raised CA$7.9 million (US$6 million) in series A funding to help health care organizations lessen COVID-19’s impact on their EMR and other operational programs. An even more ambitious goal, said CEO Nicholas Chepesiuk, is to streamline delivery of virtual health care across a range of small to large U.S.-based organizations “in a way that makes sense for their brand and their workflow.”
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cepheid, Conformis, Guide Sensmart, Oxford Immunotec, Surgical Innovation Associates.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Accelerate Technologies, Aptorum Group, Billiontoone, Confirm Biosciences, Exagen, Genosity, Infirmary Health, Inflammatix, Karl Storz, Labcorp, LC-SCRUM-Asia, Jellagen, Mayo Clinic, Olink Proteomics, Premier, Proterixbio, Provider Network of America, Pulse Biosciences, Radiant Technologies, Saranas, Securiport, Seek Thermal, Stryker, Swift Biosciences, Wright Medical, Thermo Fisher Scientific, Well Health Technologies.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acceleron, Aerie, Ascendis, BMS, Bridgebio, Histogen, Infinity, Medimetriks, Neuren, Organicell, Otsuka, Painreform, Pfizer, Seed Health, Windtree.
RSS
